Stockreport

Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference

Anavex Life Sciences Corp.  (AVXL) 
NASDAQ:AMEX Investor Relations: anavex.com/share-data
PDF New data show that blarcamesine completely rescued impaired motor function Biomarker of nerve fiber density of dopaminergic nerve cells indicating fiber regrowth in str [Read more]